Online inquiry

IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ610MR)

This product GTTS-WQ610MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets RTN4 gene. The antibody can be applied in Spinal cord injury research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001321859.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57142
UniProt ID Q9NQC3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ610MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11032MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ3372MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ14170MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ14624MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SC0001
GTTS-WQ1446MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACC-001
GTTS-WQ683MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ1627MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ11707MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MILR1444A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW